@entity4039 ( @entity4039 ) mainly occurs in pubertal @entity1 and is associated with delayed skeletal maturation, @entity28 , high growth velocity and tall stature. Furthermore, @entity4039 often coincides with @entity4903 . This is the first report of a possible relationship between @entity4039 and @entity1176 agonist treatment: four @entity1 developed @entity4039 during or shortly after treatment with @entity1176 agonists was stopped. We compared the clinical aspects of these @entity1 with @entity1 described in the literature who developed @entity4039 . Puberty started at the age of 3.3, 9.6, 0.0 and 5.6 years respectively. One @entity1 developed sequential @entity4039 of both hips. @entity4039 occurred at the age of 11.9 ( @entity1 1), 12.7 ( @entity1 2), 14.3 ( @entity1 2), 11.3 ( @entity1 3) and 11.3 ( @entity1 4) years. Of the five incidences of @entity4039 , one occurred during @entity1176 agonist treatment and four shortly after treatment was stopped. None of our @entity1 met the typical criteria seen in @entity4039 and no 'regular' characteristics of @entity1 with @entity4039 could be designated. Probably the hormonal changes during and shortly after treatment with @entity1176 agonists make the epiphysis more prone to slip. Considering our observations and by reviewing the literature, @entity1176 agonist treatment might present a risk factor for the occurrence of @entity4039 .

Can XXXX -agonist treatment cause slipped @entity4039 ?

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity1176 :: ('MESH:D007987', 'Chemical') :: ['GnRH'] @entity4039 :: ('MESH:D060048', 'Disease') :: ['Slipped capital femoral epiphysis', 'SCFE'] @entity4903 :: ('MESH:D004700', 'Disease') :: ['endocrine disorders']
@entity1176 :: (MESH:D007987,Chemical) :: ['GnRH']
